Figure 3.
Comparison of durvalumab and C5 antibodies. (a) Binding of antibodies to PD-L1 by ELISA. (b) Ability to disrupt PD-1/PD-L1 binding in the PD-1/PD-L1 blockade bioassay. (c) Amino acid sequence of durvalumab-based anti-hPD-L1 IgG4 antibody C5. The antibody does not display the ability to disrupt PD-1/PD-L1 interaction on its own.
